e-learning
resources
Virtual 2021
06.09.2021
Screening, diagnosis, management and prognosis of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy.
M. Yuan (Wuhan, China), Y. Hu (Wuhan, China), L. Wang (Wuhan, China), Y. Xiao (Wuhan, China), X. Guo (Wuhan, China)
Source:
Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer
Session:
Screening, diagnosis, management and prognosis of lung cancer
Session type:
E-poster
Number:
2182
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Yuan (Wuhan, China), Y. Hu (Wuhan, China), L. Wang (Wuhan, China), Y. Xiao (Wuhan, China), X. Guo (Wuhan, China). Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy.. 2182
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 433s
Year: 2007
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 244–259
Year: 2009
Adjuvant and neoadjuvant therapy in nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Clinical year in review
Year: 2006
Treatment of unresectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Adjuvant therapy in NSCLC
Source: Annual Congress 2007 - Clinical year in review
Year: 2007
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Use of 2
nd
-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach
Source: Eur Respir J 2003; 22: Suppl. 45, 65s
Year: 2003
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Is there any place for perioperative radiation therapy?
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Initial combined intratumoral chemotherapy with cisplatin and irradiation for inoperable non-small cell obstructive lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 492s
Year: 2004
Optimal integration of chemo- and radiotherapy in small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003
Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection?
Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications
Year: 2019
Survival of elderly patients with non-small lung cancer tretaed with combined chemotherapy and radiotherapy
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept